FDA Announces Regulatory Actions to Accelerate Psychedelic Development for Serious Mental Health Conditions

Following an executive order from President Donald J. Trump signed on April 18, 2026, the FDA announced a series of regulatory actions to support the development of serotonin 2A agonists and relation products.^1,2

The executive order signed allows federal agencies to accelerate the development and potential approval of psychedelic-based therapies for conditions including posttraumatic stress disorder (PTSD), depressive disorders, and substance use disorder (SUD). The move represents a notable shift in federal drug policy.^1,2

The FDA moved swiftly in the wake of the executive order. The agency announced it is issuing national priority vouchers to 3 companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD.

Additionally, the FDA also allowed an early phase clinical study of noribogaine hydrochloride—a derivative of ibogaine—to move forward, marking the first time a clinical study of an ibogaine derivative has been permitted in the US. The drug is being investigated as a potential treatment for alcohol use disorder, a condition with notoriously high relapse rates and limited long-term options.¹

“[W]e are accelerating the research, approval, and responsible access to promising mental health treatments—including psychedelic therapies like ibogaine—to confront our nation’s mental health crisis head-on, especially for our veterans,” Health and Human Services Secretary Robert F. Kennedy Jr said in a news release. “The FDA will prioritize therapies with breakthrough therapy designation, where early evidence shows meaningful improvement over existing options for serious mental illness.”¹

The Scale of the Problem

Over 14 million US adults are estimated to live with a serious mental illness, which is defined as a diagnosable mental, behavioral, or emotional disorder that substantially interferes with daily functioning. Existing treatments leave many of them behind. Individuals who have major depressive disorder and SUD can relapse or fail to fully respond to standard medical and psychiatric therapies.³

Specifically, veterans carry a disproportionate share of this burden. The rate of suicide among veterans in 2022 was 34.7 per 100,000, compared with 17.1 per 100,000 for nonveterans, according to RAND. For more than 2 decades, the US has struggled to close that gap, and this executive order is intended to be a direct response to that.^2,3

What the Executive Order Aims to Achieve

The executive order does not legalize psychedelic drugs. Instead, it focuses on streamlining clinical development, enhancing federal coordination, and improving access pathways for investigational therapies. The FDA stated that it will expedite review of psychedelic therapies, particularly those already designated as breakthrough therapies. This includes priority review mechanisms (eg, Commissioner's National Priority Voucher) that could significantly shorten regulatory approval timelines from the traditional 6 to 10 months to 1 to 2 months in certain cases.^1-3

The FDA and the US Drug Enforcement Administration are also directed to establish a pathway for eligible patients to access psychedelic drugs—including ibogaine compounds—under the Right to Try Act, which allows certain patients to seek experimental treatments outside the standard approval process.^1,3

The order also takes aim at drug scheduling, one of the most significant structural barriers in this space. Psychedelic substances (eg, ibogaine, psilocybin, and LSD) are still classified as Schedule I drugs under the Controlled Substances Act. However, the order calls for the attorney general to review any product containing a Schedule I substance that has completed a phase 3 trial for a serious mental health disorder, meaning that rescheduling—if appropriate—may proceed as quickly as practicable.^2,3

What Patients and Pharmacists Need to Know

For patients with treatment-resistant conditions who have exhausted conventional options, these developments signal a federal commitment to exploring more scientifically credible avenues, and if successful, the initiative could lead to the introduction of novel treatment options for patients with treatment-resistant mental health disorders, potentially reshaping pharmacologic approaches to PTSD, depression, and addiction.

Pharmacists should recognize that the executive order and FDA’s subsequent announcement signal a meaningful policy shift toward accelerating the development of psychedelic-based therapies; however, none of these agents are currently approved by the FDA, and standard requirements for demonstrating safety, efficacy, and quality remain unchanged.

Pharmacists must stay informed on evolving regulatory pathways, drug scheduling considerations, and emerging clinical data, while also preparing to counsel patients—particularly those with treatment-resistant conditions—on the investigational nature, potential risks, and uncertain long-term outcomes of these therapies. They can also help manage patient expectations amid growing public and media attention and be a source of information.

“There is a growing recognition of the potential of psychedelic medications to address multiple different psychiatric conditions that are notoriously difficult to treat,” Tracy Beth Hoeg, MD, PhD, acting director of the FDA’s Center for Drug Evaluation and Research, said in the news release. “At the FDA, we are showing our support of investigating the safety and efficacy of this class of drugs through today’s actions.”¹

REFERENCES

1. FDA accelerates action on treatments for serious mental illness following executive order. News release. FDA. April 24, 2026. Accessed April 24, 2026. https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order

2. Halpern L. Trump executive order seeks to accelerate psychedelic drug development for PTSD, addiction. Pharmacy Times. April 20, 2026. Accessed April 24, 2026. https://www.pharmacytimes.com/view/trump-executive-order-seeks-to-accelerate-psychedelic-drug-development-for-ptsd-addiction

3. Accelerating medical treatments for serious mental illness. The White House. April 18, 2026. Accessed April 24, 2026. https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/